Irbesartán Viatris

Irbesartan, the active ingredient in Irbesartán Viatris, is an Angiotensin II receptor blocker presented as an oral tablet for oral use. It is used to treat hypertension and diabetic nephropathy in adult patients.

GNH USA supplies Irbesartán Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan is an Angiotensin II receptor blocker indicated for conditions related to elevated blood pressure and renal protection.

- Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes and proteinuria. - Renal protection in hypertension: helps preserve kidney function by reducing intraglomerular pressure.

Irbesartan may cause a range of adverse reactions. Patients should be aware of both frequent and less common events.

Common Side Effects: - Dizziness: especially after the first doses or dose increases. - Headache: mild to moderate intensity. - Fatigue: general feeling of tiredness. - Nasal congestion: occasional blockage of nasal passages. - Diarrhea: loose stools without severe dehydration. - Elevated serum potassium: mild hyperkalaemia.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring urgent care. - Severe hypotension: marked drop in blood pressure causing faintness. - Acute kidney injury: sudden decline in renal function. - Hepatic dysfunction: abnormal liver enzymes. - Myocardial infarction: rare occurrence of heart attack. - Severe hyperkalaemia: dangerously high potassium levels.

Before initiating Irbesartan, clinicians should evaluate patient history and monitor relevant parameters.

- Renal function: assess creatinine and eGFR; adjust therapy if impairment is present. - Electrolytes: monitor serum potassium, especially in patients on potassium‑sparing diuretics. - Pregnancy: avoid use; potential fetal toxicity is unknown. - Concomitant ACE inhibitors or ARBs: do not combine due to risk of renal failure and hyperkalaemia. - Volume depletion: caution in patients with dehydration or on diuretics. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture and light.

Irbesartan can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - ACE inhibitors or other ARBs: combined use may cause renal dysfunction and hyperkalaemia. - Potassium‑sparing diuretics or supplements: increase risk of severe hyperkalaemia. - Aliskiren (in diabetics): may lead to renal impairment, hypotension, and hyperkalaemia.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce antihypertensive effect and impair renal function. - Lithium: can increase lithium levels, risking toxicity. - Cyclosporine or tacrolimus: may elevate serum creatinine. - Diuretics: may enhance hypotensive effect; monitor blood pressure.